Dark

Check out our Level2View

MDCX
Medicus Pharma Ltd. Common Stock
stock NASDAQ

Market Open

Sep 3, 2026 11:01:58 AM EDT

0.1800USD-29.234%(-0.0700)79,998,515

0.1500Bid 0.1500Ask 0.0000Spread

Pre-market

Sep 3, 2026 9:29:30 AM EDT

0.2003USD-21.297%(-0.0542)27,670,453

After-hours

Sep 2, 2026 4:50:30 PM EDT

0.2550USD+0.196%(0.0000)0

Overview HistoricalExchangesShortsTrends

MDCX Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

MDCX Specific Mentions

As of Sep 3, 2026 11:03:25 AM EDT (1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

2 hr ago • u/Significant_Till_718 • r/biotech_stocks • mdcx • T

3 hr ago • u/Disastrous_Ice_2147 • r/pennystocks • the_lounge • C

MDCX with huge volume

14 days ago • u/OwlZealousideal4779 • r/biotech_stocks • how_important_is_a_companys_cash_position_when_it • B

Medicus Pharma (NASDAQ: MDCX) recently reported its Q2 2026 financial results along with an update on its clinical pipeline.

One of the main things that stood out was the company's cash position. Medicus has raised approximately $40 million in financing year to date and ended Q2 with around $25.2 million in cash.

The company is also continuing to advance its two main programs. SkinJect is moving toward registrational studies for Gorlin Syndrome, while Teverelix has received regulatory clearance across urology and women's health indications.

The additional capital is expected to support upcoming Phase 2 work and registrational studies. It will be interesting to see how the clinical timeline develops from here.

For those who follow smaller biotech companies, how do you weigh a company's cash position against its upcoming clinical milestones? Is having enough funding to reach the next stage one of the main things you look at, or does the potential of the clinical data matter more?

Share